Organic salts or esters of methanesulfonic acid.
A mixture of the mesylates (methane sulfonates) of DIHYDROERGOCORNINE; DIHYDROERGOCRISTINE; and the alpha- and beta-isomers of DIHYDROERGOCRYPTINE. The substance produces a generalized peripheral vasodilation and a fall in arterial pressure and has been used to treat symptoms of mild to moderate impairment of mental function in the elderly.
The creation of an amine. It can be produced by the addition of an amino group to an organic compound or reduction of a nitro group.
A chemical element having an atomic weight of 106.4, atomic number of 46, and the symbol Pd. It is a white, ductile metal resembling platinum, and following it in abundance and importance of applications. It is used in dentistry in the form of gold, silver, and copper alloys.
BENZOIC ACID amides.
A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
All tumors in the GASTROINTESTINAL TRACT arising from mesenchymal cells (MESODERM) except those of smooth muscle cells (LEIOMYOMA) or Schwann cells (SCHWANNOMA).
Translation products of a fusion gene derived from CHROMOSOMAL TRANSLOCATION of C-ABL GENES to the genetic locus of the breakpoint cluster region gene on chromosome 22. Several different variants of the bcr-abl fusion proteins occur depending upon the precise location of the chromosomal breakpoint. These variants can be associated with distinct subtypes of leukemias such as PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; and NEUTROPHILIC LEUKEMIA, CHRONIC.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Agents that inhibit PROTEIN KINASES.
The initial phase of chronic myeloid leukemia consisting of an relatively indolent period lasting from 4 to 7 years. Patients range from asymptomatic to those exhibiting ANEMIA; SPLENOMEGALY; and increased cell turnover. There are 5% or fewer blast cells in the blood and bone marrow in this phase.
A protein-tyrosine kinase receptor that is specific for STEM CELL FACTOR. This interaction is crucial for the development of hematopoietic, gonadal, and pigment stem cells. Genetic mutations that disrupt the expression of PROTO-ONCOGENE PROTEINS C-KIT are associated with PIEBALDISM, while overexpression or constitutive activation of the c-kit protein-tyrosine kinase is associated with tumorigenesis.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
A PDGF receptor that binds specifically to both PDGF-A chains and PDGF-B chains. It contains a protein-tyrosine kinase activity that is involved in SIGNAL TRANSDUCTION.
Retrovirus-associated DNA sequences (abl) originally isolated from the Abelson murine leukemia virus (Ab-MuLV). The proto-oncogene abl (c-abl) codes for a protein that is a member of the tyrosine kinase family. The human c-abl gene is located at 9q34.1 on the long arm of chromosome 9. It is activated by translocation to bcr on chromosome 22 in chronic myelogenous leukemia.
Non-receptor tyrosine kinases encoded by the C-ABL GENES. They are distributed in both the cytoplasm and the nucleus. c-Abl plays a role in normal HEMATOPOIESIS especially of the myeloid lineage. Oncogenic transformation of c-abl arises when specific N-terminal amino acids are deleted, releasing the kinase from negative regulation.
An ERYTHROLEUKEMIA cell line derived from a CHRONIC MYELOID LEUKEMIA patient in BLAST CRISIS.
An advanced phase of chronic myelogenous leukemia, characterized by a rapid increase in the proportion of immature white blood cells (blasts) in the blood and bone marrow to greater than 30%.
Protein kinases that catalyze the PHOSPHORYLATION of TYROSINE residues in proteins with ATP or other nucleotides as phosphate donors.
Examination of CHROMOSOMES to diagnose, classify, screen for, or manage genetic diseases and abnormalities. Following preparation of the sample, KARYOTYPING is performed and/or the specific chromosomes are analyzed.
Tumors or cancer of the GASTROINTESTINAL TRACT, from the MOUTH to the ANAL CANAL.
An aberrant form of human CHROMOSOME 22 characterized by translocation of the distal end of chromosome 9 from 9q34, to the long arm of chromosome 22 at 22q11. It is present in the bone marrow cells of 80 to 90 per cent of patients with chronic myelocytic leukemia (LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE).
A heterogeneous group of disorders with the common feature of prolonged eosinophilia of unknown cause and associated organ system dysfunction, including the heart, central nervous system, kidneys, lungs, gastrointestinal tract, and skin. There is a massive increase in the number of EOSINOPHILS in the blood, mimicking leukemia, and extensive eosinophilic infiltration of the various organs.
A myelodysplastic/myeloproliferative disorder characterized by myelodysplasia associated with bone marrow and peripheral blood patterns similar to CHRONIC MYELOID LEUKEMIA, but cytogenetically lacking a PHILADELPHIA CHROMOSOME or bcr/abl fusion gene (GENES, ABL).
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Component of the NATIONAL INSTITUTES OF HEALTH. Through basic and clinical biomedical research and training, it conducts and supports research with the objective of cancer prevention, early stage identification and elimination. This Institute was established in 1937.
Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.
An abnormal hardening or increased density of bone tissue.
A de novo myeloproliferation arising from an abnormal stem cell. It is characterized by the replacement of bone marrow by fibrous tissue, a process that is mediated by CYTOKINES arising from the abnormal clone.
The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.
Informed consent given by someone other than the patient or research subject.
The terms, expressions, designations, or symbols used in a particular science, discipline, or specialized subject area.
Freedom from exposure to danger and protection from the occurrence or risk of injury or loss. It suggests optimal precautions in the workplace, on the street, in the home, etc., and includes personal safety as well as the safety of property.
A malignant tumor of the bone which always arises in the medullary tissue, occurring more often in cylindrical bones. The tumor occurs usually before the age of 20, about twice as frequently in males as in females.
A bibliographic database that includes MEDLINE as its primary subset. It is produced by the National Center for Biotechnology Information (NCBI), part of the NATIONAL LIBRARY OF MEDICINE. PubMed, which is searchable through NLM's Web site, also includes access to additional citations to selected life sciences journals not in MEDLINE, and links to other resources such as the full-text of articles at participating publishers' Web sites, NCBI's molecular biology databases, and PubMed Central.
Analog or digital communications device in which the user has a wireless connection from a telephone to a nearby transmitter. It is termed cellular because the service area is divided into multiple "cells." As the user moves from one cell area to another, the call is transferred to the local transmitter.
A gland in males that surrounds the neck of the URINARY BLADDER and the URETHRA. It secretes a substance that liquefies coagulated semen. It is situated in the pelvic cavity behind the lower part of the PUBIC SYMPHYSIS, above the deep layer of the triangular ligament, and rests upon the RECTUM.
An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.
Functionalization of exogenous substances to prepare them for conjugation in PHASE II DETOXIFICATION. Phase I enzymes include CYTOCHROME P450 enzymes and some OXIDOREDUCTASES. Excess induction of phase I over phase II detoxification leads to higher levels of FREE RADICALS that can induce CANCER and other cell damage. Induction or antagonism of phase I detoxication is the basis of a number of DRUG INTERACTIONS.
Solid dosage forms, of varying weight, size, and shape, which may be molded or compressed, and which contain a medicinal substance in pure or diluted form. (Dorland, 28th ed)
Etienne, Gabriel; Cony-Makhoul, Pascale; Mahon, François-Xavier (8 August 2002). "Imatinib Mesylate and Gray Hair". New England ... It is not yet known whether imatinib has an effect on catalase, or if its reversal of the graying process is due to something ... Nevertheless, if the mechanism of action of imatinib on melanocyte stem cells can be discovered, it is possible that a safer ... The anti-cancer drug imatinib has recently been shown to reverse the graying process. However, it is expensive and has ...
2004). "Imatinib mesylate in chordoma" (PDF). Cancer. 101 (9): 2086-97. doi:10.1002/cncr.20618. hdl:2434/642716. PMID 15372471 ... The same group in Italy found that the combination of imatinib and sirolimus caused a response in several patients whose tumors ... however a clinical trial conducted in Italy using the PDGFR inhibitor Imatinib demonstrated a modest response in some chordoma ... progressed on imatinib alone.Erlotinib like EGFR inhibitors have been also reported to be effective in Chordoma. Though EGFR ...
"Imatinib Mesylate and Gray Hair". New England Journal of Medicine. 347 (6): 446-446. doi:10.1056/NEJM200208083470614. PMID ... The anti-cancer drug imatinib has recently been shown to reverse the graying process.[24] However, it is expensive and has ... It is not yet known whether imatinib has an effect on catalase, or if its reversal of the graying process is due to something ... Nevertheless, if the mechanism of action of imatinib on melanocyte stem cells can be discovered, it is possible that a safer ...
"Imatinib mesylate for platelet-derived growth factor receptor-beta-positive Erdheim-Chester histiocytosis". Blood. 111 (11): ... "Response of Histiocytoses to Imatinib Mesylate: Fire to Ashes". Journal of Clinical Oncology. 28 (31): e633-6. doi:10.1200/JCO. ...
... imatinib mesylate) while the 1993 patent application did not claim any specific salts nor did it mention mesylate, and the 1998 ... The solid form of imatinib mesylate in Gleevec is beta crystalline. As provided under the TRIPS agreement, Novartis applied for ... The patent application claimed the final form of Gleevec (the beta crystalline form of imatinib mesylate). In 1993, before ... imatinib mesylate (Gleevec/Glivec), cyclosporine (Neoral/Sandimmune), letrozole (Femara), methylphenidate (Ritalin) (production ...
Imatinib mesylate: a new oral targeted therapy, New Eng J Med. 2002, 346:683-93. Tiersten A. D., Nelsen C., Talbot S., Vahdat L ...
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. New England Journal of Medicine. 347:472- ... "Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors". New England Journal of Medicine. 347 (7 ... George Demetri to develop imatinib as a treatment for GIST. When he started his own laboratory at the University of ...
Gal H, Pandi G, Kanner AA, Ram Z, Lithwick-Yanai G, Amariglio N, Rechavi G, Givol D (2008). "MIR-451 and Imatinib mesylate ...
... imatinib mesylate) for the treatment of DFSP. As is true for all medicinal drugs that have a name that ends in "ib," imatinib ... "Lupin in alliance with Natco receives FDA approval for Imatinib Mesylate Tablets". Lupin. Retrieved 2020-06-10. Mavili, M. E.; ... It is suggested that imatinib may be a treatment for challenging, locally advanced disease and in the rare metastatic cases It ... There is clinical evidence that imatinib, which inhibits PDGF-receptors, may be effective for tumors positive for the t(17;22) ...
"MIR-451 and Imatinib mesylate inhibit tumor growth of Glioblastoma stem cells". Biochemical and Biophysical Research ...
"Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor." Molecular Cancer Therapeutics ...
... imatinib mesylate) while the 1993 patent application did not claim any specific salts nor did it mention mesylate, and the 1998 ... The patent application[94][95] claimed the final form of Gleevec (the beta crystalline form of imatinib mesylate).[96]:3 In ... The solid form of imatinib mesylate in Gleevec is beta crystalline.[99] ... imatinib mesylate (Gleevec/Glivec), ciclosporin (Neoral/Sandimmun), letrozole (Femara), methylphenidate (Ritalin), terbinafine ...
Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate. Scheinfeld N. J Drugs ... imatinib, a tyrosine kinase inhibitor. NEH has also been described without any known reason (idiopathic cases), including ...
DeCaprio, James A.; Duensing, Anette (July 2014). "The DREAM complex in antitumor activity of imatinib mesylate in ... "The DREAM Complex Mediates GIST Cell Quiescence and Is a Novel Therapeutic Target to Enhance Imatinib-Induced Apoptosis". ... targeting the DREAM complex might enhance anticancer treatments such as imatinib. Pocket protein family Sadasivam, Subhashini; ...
"Imatinib Mesylate Inhibits Leydig Cell Tumor Growth: Evidence for In vitro and In vivo Activity". Cancer Research. 65 (5): 1897 ... although imatinib has shown some promise. There is no current role for radiotherapy. The usual treatment is surgery. The ...
Novartis had attempted to patent imatinib mesylate in beta crystalline form (rather than imatinib or imatinib mesylate), thus ... that imatinib mesylate in beta crystalline form has enhanced efficacy over imatinib or imatinib mesylate to pass the test of ... the mesylate salt of imatinib). The "beta crystalline form" of the molecule is a specific polymorph of imatinib mesylate; a ... the beta crystalline form of Imatinib Mesylate being a pharmaceutical substance and moreover a polymorph of Imatinib Mesylate, ...
It was marketed in 2001 by Novartis as imatinib mesylate (Gleevec in the US, Glivec in Europe). Other pharmacological ... Tyrosine kinase inhibitors specific to such domains as CC, Y177, and Rho (such as imatinib and sunitinib) are important drugs ... In the late 1990s, STI-571 (imatinib, Gleevec/Glivec) was identified by the pharmaceutical company Novartis (then known as Ciba ... New inhibitors include dasatinib and nilotinib, which are significantly more potent than imatinib and may overcome resistance. ...
Imatinib mesylate works to block BCR-Abl's activity by blocking the active kinase domain (Fava et al., 2011). Celastrol is a ... The developed tyrosine kinase inhibitor, imatinib mesylate, has had a tremendous effect on stopping cancer progression in the ... "Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib". Journal of the ...
A Phase II trial of imatinib mesylate (Gleevec) in neuroendocrine carcinoma of the skin (Merkel Cell Carcinoma) (S0331). ... "A phase II trial of imatinib mesylate in Merkel cell carcinoma (neuroendocrine carcinoma of the skin): A Southwest Oncology ... "A phase II trial of imatinib mesylate in merkel cell carcinoma (neuroendocrine carcinoma of the skin): A Southwest Oncology ...
Imatinib mesylate (Gleevec) - National Cancer Institute Archived October 15, 2007, at the Wayback Machine How's Carole Migden's ...
The classic example of targeted development is imatinib mesylate (Gleevec), a small molecule which inhibits a signaling ... From these, imatinib was found to have the most promise in laboratory experiments. First Druker and then other groups worldwide ... Imatinib precisely inhibits this kinase. Unlike so many other anti-cancer agents, this pharmaceutical was no accident. Brian ... March 2003). "Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid ...
... most notably Imatinib-mesylate in gastrointestinal stromal tumors (GISTs). Tyrosine kinase (a subclass of protein kinases) is ... experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571)". European Journal of Cancer. 38 (Suppl 5): ...
One such inhibitor is imatinib mesylate, which occupies the tyrosine kinase domain and inhibits BCR-ABL's influence on the cell ... "Entrez Gene: ABL1 v-abl Abelson murine leukemia viral oncogene homolog 1". Shah, N. P. (2004-07-16). "Overriding Imatinib ... generation BCR-ABL tyrosine-kinase inhibitors are also under development to inhibit BCR-ABL mutants resistant to imatinib. ABL ...
... occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy". Blood. 102 (9 ... 2003). "A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic ... Helbig G (February 2018). "Imatinib for the treatment of hypereosinophilic syndromes". Expert Review of Clinical Immunology. 14 ... Imatinib. This drug, also known as Gleevec, has been a FDA-approved and most successful treatment for Philadelphia chromosome- ...
KIT-D816V point mutations in c-KIT exon 17 are responsible for resistance to targeted therapy drugs like imatinib mesylate, a ... imatinib, sunitinib, and regorafenib. Imatinib (Glivec/Gleevec), an orally administered drug initially marketed for chronic ... Imatinib has been used in selected neoadjuvant settings. In the adjuvant treatment setting, the majority of GIST tumors are ... The selection criteria underpinning the decision for possible use of imatinib in these settings include a risk assessment based ...
The first of this new class of drugs was imatinib mesylate (marketed as Gleevec or Glivec), approved by the US Food and Drug ... Imatinib was found to inhibit the progression of CML in the majority of patients (65-75%) sufficiently to achieve regrowth of ... Since the advent of imatinib, CML has become the first cancer in which a standard medical treatment may give to the patient a ... To overcome imatinib resistance and to increase responsiveness to TK inhibitors, four novel agents were later developed. The ...
... versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing ... However Imatinib, as an inhibitor to the malfunctioning enzyme, can be effective. If imatinib does not work, patients with ... Imatinib (brand names Gleevec and Glivec) is a drug able to bind the catalytic cleft of these tyrosine kinases, inhibiting its ... Therapy with imatinib can inhibit the non-normal cell signaling mechanisms in gastrointestinal stromal tumors. This results in ...
... who have been previously treated with imatinib mesylate and sunitinib malate. Regorafenib is a compound developed by Bayer. The ...
"A novel mechanism for imatinib mesylate-induced cell death of BCR-ABL-positive human leukemic cells: caspase-independent, ...
... can be targeted to increase the efficacy of imatinib mesylate against BCR/ABL-positive leukemia cells". Blood. 110 (2): 651-60 ...
... standard of care for all patients with CML and is extremely valuable for patients being treated with imatinib mesylate (Gleevec ...
"Imatinib mesylate". Drug Information Portal. U.S. National Library of Medicine.. *. "Imatinib mesylate". National Cancer ... the mesylate salt of imatinib). The "beta crystalline form" of the molecule is a specific polymorph of imatinib mesylate; a ... imatinib mesylate) while the 1993 patent application did not claim any specific salts nor did it mention mesylate, and the 1998 ... imatinib mesylate appears to have utility in the treatment of a variety of dermatological diseases. Imatinib has been reported ...
... imatinib, though it is still in use to a degree as a result of the drug's relative low cost. ... This occurs through an SN2 reaction in which the relatively nucleophilic guanine N7 attacks the carbon adjacent to the mesylate ...
This first targeted cancer therapy, imatinib mesylate, or Gleevec, contributed to a major breakthrough in the treatment of ...
... as in imatinib mesilate, the mesylate salt of imatinib). Mesylate esters are a group of organic compounds that share a common ... In chemistry, a mesylate is any salt or ester of methanesulfonic acid (CH3SO3H). In salts, the mesylate is present as the ... Mesylate is considered a leaving group in nucleophilic substitution reactions. Mesylates are generally prepared by treating an ... Related to mesylate is the mesyl (Ms) or methanesulfonyl (CH3SO2) functional group. Methanesulfonyl chloride is often referred ...
... and BCR-ABL amplification occurs in response to imatinib mesylate. Determining areas of gene amplification in cells from cancer ... involves a tyrosine kinase inhibitor that targets the BCR/ABL fusion gene called imatinib. In some people resistant to Imatinib ... In Imatinib resistant cell lines, silencing of the SOCS-3 gene via methylation has been shown to cause STAT3 protein activation ... Nardi, Valentina; Azam, Mohammad; Daley, George Q. (2004-01-01). "Mechanisms and implications of imatinib resistance mutations ...
"Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patients with Plexiform ... Early research has shown potential for using the c-kit tyrosine kinase blocking properties of imatinib to treat plexiform ...
... imatinib mesylate - imipenem - imiquimod - immune adjuvant - immune function - immune response - immune system - immune system ... exatecan mesylate - excision - excisional biopsy - exemestane - exisulind - exocrine pancreas cell - expanded access trial - ... crisnatol mesylate - Crohn's disease - cryopreservation - cryosurgery - cryotherapy - cryptorchidism - CSF - CT scan - CT-2103 ... saquinavir mesylate - sarCNU - sarcoma - sarcosinamide nitrosourea - sargramostim - satraplatin - SC-70935 - SCH 54031 - SCH ...
Imatinib Mesylate News and Research. RSS Imatinib mesylate (also called Gleevec® or STI571) is approved by the U.S. Food and ... The drug Gleevec (imatinib mesylate) is well known not only for its effectiveness against chronic myeloid leukemia (CML) and ... Imatinib mesylate effectively treats children with neurofibromatosis type 1 tumors Physician-researchers at Indiana University ... In GIST, imatinib blocks a different abnormal enzyme found on the tumor cells. Imatinib is the first approved drug to directly ...
Find information about Imatinib mesylate including usage and side effects. Browse our Drug Dictionary for generic drug names ... Imatinib mesylate is FDA approved to treat. *Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive ... Patients Disease Information Treatment Types of Treatment Chemotherapy and Other Drug Therapies Drug Listings Imatinib mesylate ...
Imatinib Mesylate, Videos - Imatinib Mesylate. Imatinib Mesylate updates on Rediff News ... Buy Generic Imatinib Mesylate 400mg... Imatinib mesylate 400mg tablets is a.... 1 Followers ... Buy Imatinib Mesylate 100mg Capsules... Imatinib mesylate 100mg is a.... 1 Followers ... Buy Imatinib Mesylate 100mg Online Imatinib mesylate 100mg tablets is.... 1 Followers ...
Binimetinib and imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.. ... Ipilimumab and Imatinib Mesylate in Advanced Cancer The goal of this clinical research study is to find the highest tolerable ... Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in ... Binimetinib and Imatinib Mesylate in Treating Patients with Untreated Advanced Gastrointestinal Stromal Tumors This phase Ib / ...
Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor.. Rink L1, Skorobogatko Y, ... As part of a recent phase II trial of neoadjuvant/adjuvant imatinib mesylate treatment for advanced primary and recurrent ... Despite initial efficacy of imatinib mesylate in most gastrointestinal stromal tumor (GIST) patients, many experience primary/ ... Gene Expression Signatures and Response to Imatinib Mesylate in Gastrointestinal Stromal Tumor ...
Breckenridges Imatinib Mesylate Tablets product was developed in collaboration with Stason Pharmaceuticals Inc. and will be ... Breckenridge Announces Final Approval of its ANDA for Imatinib Mesylate Tablets (RLD: Gleevec®). News provided by ... Breckenridge Announces Final Approval of its ANDA for Imatinib Mesylate Tablets (RLD: Gleevec®) ... Food and Drug Administration has granted final approval for its Abbreviated New Drug Application for Imatinib Mesylate Tablets ...
Sun Pharmas Imatinib Mesylate Savings Card will also offer patients additional savings benefit of up to US$700 for a 30-day ... Imatinib Mesylate is a kinase inhibitor indicated for the treatment of:. Newly diagnosed adult and pediatric patients with ... The company has rolled-out Sun Pharma Imatinib Mesylate Savings Card program. This program aims to deliver greater access to ... As per FDA approval letter, Sun Pharmas Imatinib Mesylate ANDA contains a statement that its application did not seek approval ...
Use and Tolerability of Imatinib Mesylate (Gleevec) in Leukemia Patients. Official Title ICMJE Use and Tolerability of Imatinib ... Use and Tolerability of Imatinib Mesylate (Gleevec) in Leukemia Patients. The safety and scientific validity of this study is ... Drug: Imatinib Mesylate Starting dose of 100 mg daily by mouth for first 100 days following bone marrow transplant (BMT) or ... Imatinib mesylate is an FDA-approved, commercially available drug for patients with acute or chronic leukemias carrying the ...
Imatinib Mesylate in Treating Patients With Myelofibrosis. Official Title ICMJE A Phase II Study Of Gleevec (Imatinib Mesylate ... Experimental: Treatment (imatinib mesylate) Patients receive oral imatinib mesylate once or twice daily on days 1-28. Courses ... Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have myelofibrosis. Imatinib mesylate ... Imatinib Mesylate in Treating Patients With Myelofibrosis. The safety and scientific validity of this study is the ...
Imatinib mesylate , C30H35N7O4S , CID 123596 - structure, chemical names, physical and chemical properties, classification, ...
Imatinib mesylate represents the first of a new generation of molecularly targeted therapies engineered to disrupt signal ... Imatinib mesylate--gold standards and silver linings Clin Exp Med. 2004 Sep;4(1):1-9. doi: 10.1007/s10238-004-0032-5. ... Imatinib mesylate represents the first of a new generation of molecularly targeted therapies engineered to disrupt signal ... Imatinib inhibits this activity, inducing remarkable rates of hematological and cytogenetic remission in excess of those seen ...
Imatinib induced a sustained objective response in more than half of patients with an advanced unresectable or metastatic ... Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med. 2002 Aug 15;347(7):472-80. ... Imatinib mesylate, a selective tyrosine kinase inhibitor, has been shown in preclinical models and preliminary clinical studies ... Conclusions: Imatinib induced a sustained objective response in more than half of patients with an advanced unresectable or ...
Imatinib mesylate (imatinib) is a tyrosine kinase inhibitor developed to treat Bcr/Abl-expressing leukemias and subsequently ... Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. ... Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. ... In our studies, imatinib attenuated PDGFR signaling in fibroblast-like synoviocytes (FLSs) and TNF-α production in synovial ...
Imatinib mesylate is a drug that blocks certain proteins that play a part in the development. of cancer. Imatinib mesylate has ... mesylate. Depending on when you begin treatment on this study, you may be asked to take 3,. 4, or 6 tablets of imatinib ... imatinib mesylate tablets every day up to 1 month after the 6 treatment cycles. If you. develop any intolerable side effects or ... Prior exposure to imatinib mesylate.. 16. Patients taking therapeutic levels of warfarin. However, patients receiving 1 mg. ...
Research Report on Global Imatinib Mesylate Market Research Report 2017. The Report includes market price, demand, trends, size ... Table Global Imatinib Mesylate Price (USD/MT) by Type (2012-2017). Figure Global Imatinib Mesylate Production Growth by Type ( ... Table Global Imatinib Mesylate Revenue (Million USD) by Type (2012-2017). Table Global Imatinib Mesylate Revenue Share by Type ... Figure Global Imatinib Mesylate Capacity (MT) of Key Manufacturers in 2016. Figure Global Imatinib Mesylate Capacity (MT) of ...
Drug Information available for: Imatinib Imatinib mesylate Genetic and Rare Diseases Information Center resources: Myeloid ... Imatinib mesylate. tyrosine kinases. imatinib sensitivity. Diverse malignancies either associated with. or thought to be ... Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes. The safety and ... The objective of this study is to assess to what extent imatinib mesylate blocks these enzymes and to assess the effect on the ...
... c-KIT-expressing Ewing tumour cells are insensitive to imatinib mesylate (STI571). Download Prime PubMed App to iPhone, iPad, ... Despite the expression of imatinib mesylate-sensitive tyrosine kinases, Ewing tumour cells proved resistant to imatinib ... the expression of the currently known imatinib mesylate-sensitive tyrosine kinases and tested sensitivity to imatinib mesylate ... the expression of the currently known imatinib mesylate-sensitive tyrosine kinases and tested sensitivity to imatinib mesylate ...
Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in ... Does the drug imatinib mesylate help treat patients with newly diagnosed leukemia patients?. Basic Study Information. Purpose: ... Giving imatinib mesylate and combination chemotherapy may work better in treating patients with Philadelphia chromosome ... Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute ...
Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for their growth. It is not yet ... may predict the response to imatinib mesylate, markers of imatinib mesylate effect, and. potential markers of toxicity in ... of imatinib mesylate.. OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified. according to the ... Compare the efficacy of 2 different doses of imatinib mesylate, in terms of molecular. response rate at 12 months, in patients ...
Imatinib Mesylate Resistance Through BCR-ABL Independence in Chronic Myelogenous Leukemia. Nicholas J. Donato, Ji Y. Wu, ... Imatinib Mesylate Resistance Through BCR-ABL Independence in Chronic Myelogenous Leukemia. Nicholas J. Donato, Ji Y. Wu, ... Imatinib Mesylate Resistance Through BCR-ABL Independence in Chronic Myelogenous Leukemia. Nicholas J. Donato, Ji Y. Wu, ... Imatinib Mesylate Resistance Through BCR-ABL Independence in Chronic Myelogenous Leukemia Message Subject (Your Name) has ...
The Effects of Imatinib Mesylate on Spontaneous Slow-Wave Activity in the Guinea-Pig Prostate. Imatinib mesylate appeared to ... Imatinib Mesylate on Young vs Ageing Guinea-Pig Prostates. In the presence of imatinib mesylate, both age groups displayed ... N/g in imatinib mesylate, P , 0.01). Imatinib mesylate did not reduce contractile activity to the same extent in the ageing ... an event that can be suppressed by the addition of imatinib mesylate [15]. Imatinib mesylate competitively inhibits the ATP ...
Drug Information available for: Hydroxyurea Imatinib Imatinib mesylate Genetic and Rare Diseases Information Center resources: ... Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma. The safety and ... RATIONALE: Imatinib mesylate, vatalanib, and hydroxyurea may stop the growth of tumor cells by blocking some of the enzymes ... Imatinib Mesylate. Hydroxyurea. Vatalanib. Antineoplastic Agents. Protein Kinase Inhibitors. Enzyme Inhibitors. Molecular ...
... * Home ... in combination with imatinib mesylate (Gleevec) in patients with chronic phase, accelerated phase, and blast crisis CML; (2) to ... activity in combination with imatinib mesylate. Thus, the objectives to the study are (1) to determine the maximum tolerated ...
Imatinib Mesylate Treatment for Advanced Gastrointestinal Stromal Tumor A Pilot Study Focusing on Patients Experiencing Sole ... Zhu, J., Wang, Y., Hou, M., Li, H.Y. and Zhang, J. (2007) Imatinib Mesylate Treatment for Advanced Gastrointestinal Stromal ...
Imatinib mesylate was administered at a dose of 600 mg, which has been shown to be superior to 400 mg in the pivotal study in ... The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Michael E. ODwyer, Michael ... In this phase 2 study, 400 mg of imatinib mesylate was used daily.23 Although obviously a small group, our AP-CE patients had ... Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645-652. ...
Food and Drug Administration has granted final approval for its Abbreviated New Drug Application for Imatinib Mesylate Tablets ... Breckenridges Imatinib Mesylate Tablets product was developed in collaboration with Stason Pharmaceuticals Inc. and will be ... Breckenridge Announces Final Approval of its ANDA for Imatinib Mesylate Tablets (RLD: Gleevec®) ... www.prnewswire.com/news-releases/breckenridge-announces-final-approval-of-its-anda-for-imatinib-mesylate-tablets-rld-gleevec- ...
Imatinib Mesylate inhibits c-kit, PDGFR and c-ABL by perfectly binding to adenosine triphosphate (ATP)-binding sites of the c- ... Imatinib Mesylate would induce cytogenetic remissions in the majority of chronic myeloid leukemia patients. Imatinib Mesylate ... Imatinib Mesylate inhibits c-kit, PDGFR and c-ABL by perfectly binding to adenosine triphosphate (ATP)-binding sites of the c- ... Imatinib Mesylate inhibits c-kit, PDGFR and c-ABL by perfectly binding to adenosine triphosphate (ATP)-binding sites of the c- ...
Example 1: benzyl Alcohol Used Imatinib Mesylate Preparation of Form F About 500 mg of imatinib mesylate is first dissolved in ... F, V, H, I and V crystal forms of imatinib mesylate {F, G, H, I AND K CRYSTAL FORMS OF IMATINIB MESYLATE}. The invention ... i and k crystal forms of imatinib mesylate - Google Patents. F, g, h, i and k crystal forms of imatinib mesylate Download PDF ... Delta and epsilon crystal forms of imatinib mesylate KR20130141712A (en) * 2005-11-25. 2013-12-26. 노파르티스 아게. F, g, h, i and k ...
Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma. Purpose. Determine the highest tolerable dose of drug ... Prior exposure to imatinib mesylate.. *Patients taking therapeutic levels of warfarin. However, patients receiving 1 mg daily ... To determine the doses of the combination regimen of cisplatin, imatinib mesylate, and pemetrexed that enables de- ... To determine the maximum tolerated dose of the combination of cisplatin, imatinib mesylate, and pemetrexed in metastatic ...
Veenat 400mg Imatinib Tablets Details : Brand Name : Veenat Tablets Generic Salt : Imatinib Mesylate Strength : 400mg Packing ... Veenat 400mg Imatinib Tablets Details :. Brand Name : Veenat Tablets. Generic Salt : Imatinib Mesylate. Strength : 400mg. ... Buy Cipla Imatinib Mesylate 400 Mg Tablets Online - Fitness Classified Ads in United. ...
  • Imatinib mesylate (also called Gleevec® or STI571) is approved by the U.S. Food and Drug Administration (FDA) for the treatment of some forms of adult and pediatric chronic myelogenous leukemia (CML), and for the treatment of a rare form of cancer called gastrointestinal stromal tumor (GIST). (news-medical.net)
  • The drug Gleevec (imatinib mesylate) is well known not only for its effectiveness against chronic myeloid leukemia (CML) and acute lymphoblastic leukemia, but also for the story behinds its development. (news-medical.net)
  • BOCA RATON, Fla. , March 4, 2019 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc. announced that the U.S. Food and Drug Administration has granted final approval for its Abbreviated New Drug Application for Imatinib Mesylate Tablets, generic for Gleevec® Tablets by Novartis. (prnewswire.com)
  • NEW JERSEY, Feb. 1, 2016 /PRNewswire/ -- Sun Pharma announced launch of Imatinib Mesylate Tablets (therapeutic equivalent to Gleevec® for indications approved by the FDA) in the US market. (fiercepharma.com)
  • Determine the highest tolerable dose of drug combination (cisplatin, pemetrexed [ Alimta ®], and imatinib mesylate [Gleevec®]) that can be given to patients with unresectable or metastatic malignant mesothelioma . (mesotheliomacenter.org)
  • FDA Approves Novartis` Unique Leukemia Medication Gleevec(TM)* (imatinib mesylate) (PR Newswire)Novartis today announced that the United States Food and Drug Administration approved its drug Gleevec(TM) as an oral therapy for the treatment of patients with chronic myeloid leukemia in the blast crisis, accelerated phase or in chronic phase after failure of interferon-alpha therapy. (virtualtrials.com)
  • Imatinib mesylate (Gleevec, Novartis Pharmaceuticals East Manruer, NJ) received accelerated approval on May 10, 2001 for the treatment of patients with chronic myeloid leukemia (CML) in ( a ) chronic phase after failure of IFN-α therapy, ( b ) accelerated phase, and ( c ) blast crisis. (aacrjournals.org)
  • On December 5, 2003, the U.S. Food and Drug Administration converted the approval of imatinib mesylate tablets (Gleevec, Novartis Pharmaceuticals) for the treatment of adult patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in ( a ) chronic phase after failure of IFN-α therapy, ( b ) accelerated phase, and ( c ) blast crisis from accelerated to regular approval. (aacrjournals.org)
  • Pharma major Lupin Limited (Lupin) and Natco Pharma Limited (Natco) announced the final ANDA approval for Imatinib Mesylate Tablets, 100 mg (base) and 400 mg (base) from the United States Food and Drug Administration (FDA) to market a generic version of Novartis Pharmaceuticals Corporation's (Novartis) Gleevec® Tablets, 100mg and 400mg. (lupin.com)
  • Lupin and Natco's Imatinib Mesylate Tablets, 100 mg (base) and 400 mg (base) is the generic version of Novartis' Gleevec® Tablets, 100 mg and 400 mg. (lupin.com)
  • Lees ook het artikel over goede resultaten van dasatinib en nilotinib bij CML en ALL in vergelijking met Gleevec. (kanker-actueel.nl)
  • Met Gleevec, zie onderstaand artikel, is heel veel meer onderzoek gedaan afgelopen jaren en de opvolgers, Nipent en Sugent worden ook al weer enkele jaren in de praktijk toegepast. (kanker-actueel.nl)
  • Het volgende artikel is afgeleid van de studiepublicatie in de New England Journal of Medicine en geeft aan dat het middel Imatinib Mesylate (een andere naam voor Gleevec) bijzonder hoge respons gaf bij 454 patiënten in het M.D. Anderson Kankercentrum in Houston waar de normale standaard behandeling met bv. (kanker-actueel.nl)
  • Opvallend is dat op de website van het M.D. Anderson Kankercentrum zelfs deze behandeling met Imatinib Mesylate (Gleevec) nu wordt verkozen boven een beenmerg- of stamceltransplantatie. (kanker-actueel.nl)
  • Voor meer informatie over trials met Imatinib Mesylate (Gleevec) zie deze websitepagina van het M.D. Anderson Kankercentrum. (kanker-actueel.nl)
  • The generic name of Gleevec is imatinib mesylate. (ndclist.com)
  • Gleevec (imatinib mesylate) is a protein-tyrosine kinase inhibitor that blocks the constitutive abnormal tyrosine kinase, Bcr-Abl tyrosine kinase, that is created by the Philadelphia chromosome abnormality found in CML. (centerwatch.com)
  • For over fifteen years, GLEEVEC ® (imatinib mesylate) tablets has supported patients and is proud to continue providing that support today. (gleevec.com)
  • We have the Gleevec generic, called Imatinib Mesylate, available as well. (mydrugcenter.com)
  • When doing a price comparison of the Gleevec brand or the Imatinib Mesylate generic alternative, huge savings are revealed. (mydrugcenter.com)
  • Gleevec comes in tablet form for oral administration and it contains the active ingredient Imatinib Mesylat. (mydrugcenter.com)
  • We continue to develop and design superior quality products for both our old and new customers and achieve a win-win prospect for our clients as well as us for Imatinib Mesylate , imatinib mesylate , Imatinib Mesylate Gleevec , we have been paying attention on all information to insure each product or service glad by our customers. (il67.icu)
  • GLEEVEC ® (imatinib mesylate) is available only by prescription. (gleevec.com)
  • Let us develop prosperous future hand in hand for Imatinib Mesylate Side Effects , imatinib mesylate side effects , Imatinib Mesylate Gleevec , We sincerely welcome friends from all over the world to cooperate with us on the basis of long-term mutual benefits. (pharmachemm.com)
  • Generic Gleevec (Imatinib Mesylate tablets) is used for the treatment of newly diagnosed adult patients with Philadelphia chromosome positive chronic myeloid leukemia (CML) in chronic phase. (clearskypharmacy.biz)
  • The recommended dosage of Generic Gleevec (Imatinib Mesylate tablets) is 400 mg/day for adult patients in chronic phase CML and 600 mg/day for adult patients in accelerated phase or blast crisis. (clearskypharmacy.biz)
  • Rare cases of Generic Gleevec (Imatinib Mesylate) overdose have been reported. (clearskypharmacy.biz)
  • Imatinib, sold under the brand name Gleevec among others, is an oral chemotherapy medication used to treat cancer. (wikipedia.org)
  • Imatinib mesylate 100mg tablets is. (rediff.com)
  • Breckenridge's Imatinib Mesylate Tablets product was developed in collaboration with Stason Pharmaceuticals Inc. and will be commercially manufactured by Stason in 100mg and 400mg product strengths. (prnewswire.com)
  • Depending on when you begin treatment on this study, you may be asked to take 3, 4, or 6 tablets of imatinib mesylate by mouth once a day. (knowcancer.com)
  • After you complete 6 treatment cycles of cisplatin and pemetrexed, you will continue to take imatinib mesylate tablets every day up to 1 month after the 6 treatment cycles. (knowcancer.com)
  • According to IQVIA, US sales of Imatinib Mesylate Tablets were approximately $831 million in the 12 months ending August 2018. (hikma.com)
  • Imatinib Mesylate Tablets, 100 mg (base) and 400 mg (base) had annual sales of approximately USD 655 mn in the US (IQVIA MAT December 2018). (lupin.com)
  • We are exporter of Imatib Mesylate Tablets 400 Mg. (3spharmaceuticals.com)
  • Storage Instructions Store Imatinib Tablets in a cool, dry place, away from direct heat and light. (heethealthcare.co.in)
  • Imatinib Mesylate tablets are also used for the treatment of patients with Philadelphia chromosome positive chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy. (clearskypharmacy.biz)
  • Imatinib Mesylate tablets are also used to treat patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). (clearskypharmacy.biz)
  • We also have in stock Veenat (Imatinib Mesylate Tablets) which are used for the treatment of adult and paediatric patients with Ph+ CML (Philadelphia chromosome-positive chronic myeloid leukaemia) as well as to treat patients with Kit (CD117) positive unresectable and/or metastatic malignant GIST (gastrointestinal stromal tumours). (clearskypharmacy.biz)
  • The active ingredient present in Imalek tablets is Imatinib Mesylate. (clearskypharmacy.biz)
  • The recommended dosage of Imatinib Mesylate tablets is 400 mg/day or 600 mg/day for adult patients with unresectable and/or metastatic, malignant GIST. (clearskypharmacy.biz)
  • Take Imatinib Mesylate tablets exactly as prescribed by your doctor. (clearskypharmacy.biz)
  • Imatinib tablets (Imalek) are contraindicated in patients with a hypersensitivity to Imatinib Mesylate or any inactive ingredient present in Imalek tablets. (clearskypharmacy.biz)
  • Get All Imatinib 400mg Tablets Imatib wholesale Price Used to treat chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (all), myeloproliferative disorder etc Know the uses, side effects, price, composition, substitutes, How it works, where to buy ,Precautions and Expert Advice for Imatinib 400mgTablet manufactured by Cipla LTD India. (medsdelta.com)
  • Imatinib mesylate, glivec 400mg an. (rediff.com)
  • Cheap Generic for Imatinib Mesylate 400mg interferes with the growth of some cancer cells. (completeonlinepharmacy.com)
  • Cheap Generic for Imatinib Mesylate 400mg is used to treat a certain types of leukemia (blood cancer) such as Philadelphia chromosome positive chronic myeloid leukemia (CML). (completeonlinepharmacy.com)
  • Cheap Generic for Imatinib Mesylate 400mg may also be used for purposes not listed in this medication guide. (completeonlinepharmacy.com)
  • Do not use Generic for Imatinib Mesylate 400mg if you are pregnant. (completeonlinepharmacy.com)
  • Before using Generic for Imatinib Mesylate 400mg , tell your doctor if you have liver disease, kidney disease, underactive thyroid, congestive heart failure, a history of stomach ulcer or bleeding, or if you are receiving chemotherapy. (completeonlinepharmacy.com)
  • Generic for Imatinib Mesylate 400mg should be taken with a meal. (completeonlinepharmacy.com)
  • To be sure Generic for Imatinib Mesylate 400mg is not causing harmful effects, your blood may need to be tested often. (completeonlinepharmacy.com)
  • Take Generic for Imatinib Mesylate 400mg exactly as prescribed by your doctor. (completeonlinepharmacy.com)
  • You may dissolve the Generic for Imatinib Mesylate 400mg Tablet in water or apple juice to make swallowing easier. (completeonlinepharmacy.com)
  • Do not take Generic for Imatinib Mesylate 400mg on an empty stomach. (completeonlinepharmacy.com)
  • Store Generic for Imatinib Mesylate 400mg at room temperature away from moisture and heat. (completeonlinepharmacy.com)
  • Treatment was initiated and maintained by administering 400mg/day imatinib mesylate. (imedicalsociety.org)
  • Imatib (Imatinib) Brand name: Imatib Active Ingeridents (Generic Name) : Imatinib Company Name : Cipla Package: 10 Tabs in strip Strength : 400mg Indication: Its use is advised against in patients on strong CYP3A4 inhibitors such as clarithromycin, chloramphenicol, ketoconazole, ritonavir andnefazodone due to its reliance on CYP3A4 for metabolism. (applepharma.us)
  • Imatinib mesylate (STI571), a selective inhibitor of the Bcr-Abl tyrosine kinase, has significant activity in AP CML. (bloodjournal.org)
  • Buchdunger Elisabeth, O'Reilley Terence, Wood Jeanette (2002): Pharmacology of imatinib (STI571). (agriculturejournals.cz)
  • Imatinib mesylate, formerly STI571, is a selective inhibitor of this kinase. (kanker-actueel.nl)
  • Therefore, clinical management of GIST may benefit from further molecular characterization of tumors before and after imatinib mesylate treatment. (nih.gov)
  • Imatinib mesylate, a selective tyrosine kinase inhibitor, has been shown in preclinical models and preliminary clinical studies to have activity against such tumors. (nih.gov)
  • Imatinib mesylate (imatinib) is a tyrosine kinase inhibitor developed to treat Bcr/Abl-expressing leukemias and subsequently found to treat c-Kit-expressing gastrointestinal stromal tumors. (jci.org)
  • DFSP is characterized by a specific fusion of the platelet-derived growth factor β (PDGFβ) with the collagen type 1α1 (COL1α1) gene which renders these tumors responsive to targeted therapy with tyrosine kinase inhibitors, such as imatinib mesylate, as is reported in adults. (eur.nl)
  • However, a subgroup of tumors show a secondary progress under therapy with imatinib after initial response. (aacrjournals.org)
  • The DREAM complex in antitumor activity of imatinib mesylate in gastrointestinal stromal tumors. (harvard.edu)
  • The role of surgery in patients with metastatic, recurrent or unresectable locally advanced gastrointestinal stromal tumors (GIST) who respond to imatinib mesylate (IM) treatment is still not formally defined. (researchsquare.com)
  • Imatinib is used to treat chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies. (wikipedia.org)
  • On 1 February 2012, imatinib was approved for use after the surgical removal of KIT-positive tumors to help prevent recurrence. (wikipedia.org)
  • Oncovet I (Chemovet S.A.), is the is the first imatinib-based drug approved in Latin America for veterinary use for canine and feline cancer (mast cell tumor, fibrosarcomas, gastrointestinal stromal tumors, hemangiosarcomas, B-cell leukemia, meningiomas, feline sarcomas associated with vaccines and hypereosinophilic syndrome in felines. (wikipedia.org)
  • In GIST, imatinib blocks a different abnormal enzyme found on the tumor cells. (news-medical.net)
  • Despite initial efficacy of imatinib mesylate in most gastrointestinal stromal tumor (GIST) patients, many experience primary/secondary drug resistance. (nih.gov)
  • Importantly, 10 KRAB-ZNF genes mapped to a single locus on chromosome 19p, and a subset predicted likely response to imatinib mesylate-based therapy in a naïve panel of GIST. (nih.gov)
  • Furthermore, we found that modifying expression of genes within this predictive signature can enhance the sensitivity of GIST cells to imatinib mesylate. (nih.gov)
  • Molecularly targeted therapy, such as imatinib therapy, has revolutionized the treatment of advanced GIST and facilitates scientific research on GIST. (springer.com)
  • Although there are some minor differences among the guidelines-for example, in the dose of imatinib recommended for exon 9-mutated GIST or the efficacy of antigen retrieval via immunohistochemistry-their common objectives regarding diagnosis and treatment are not only to improve the diagnosis of GIST and the prognosis of patients but also to control medical costs. (springer.com)
  • Imatinib inhibits the KIT and PDGFR tyrosine kinases, resulting in its notable antitumor activity in gastrointestinal stromal tumor (GIST). (elsevier.com)
  • We previously reported the early results of a multi-institutional prospective trial (RTOG 0132) using neoadjuvant/adjuvant imatinib either in primary resectable GIST or as a planned preoperative cytoreduction agent for metastatic/recurrent GIST. (elsevier.com)
  • Patients with primary GIST (≥5 cm, group A) or resectable metastatic/recurrent GIST (≥2 cm, group B) received neoadjuvant imatinib (600 mg/day) for approximately 2 months and maintenance postoperative imatinib for 2 years. (elsevier.com)
  • Existing pre-clinical and clinical data suggest that SCH66336, a farnesyl transferase inhibitor,exhibits significant activity against CML cells, and in fact may have synergistic activity in combination with imatinib mesylate. (clinicalconnection.com)
  • Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. (nih.gov)
  • Based on our results, the fludarabine- based chemotherapy regimens can be used for those patients with CML blastic phase in combination with imatinib mesylate. (tjh.com.tr)
  • Several studies have examined the functional role of tyrosine kinase receptors in the generation of spontaneous activity in various segments of the gastrointestinal and urogenital tracts through the application of its inhibitor, imatinib mesylate (Glivec®), but results are fairly inconsistent. (wiley.com)
  • To investigate the effect of imatinib mesylate, a tyrosine kinase receptor inhibitor, in the generation of spontaneous electrical and contractile activity in the young and ageing guinea-pig prostate. (wiley.com)
  • Imatinib mesylate is a specific tyrosine kinase inhibitor that may block the platelet-derived growth factor and transforming growth factor pathways. (ahajournals.org)
  • Both PDGFRα and KIT receptors are targets of the tyrosine kinase inhibitor imatinib (Glivec) which has improved the treatment of advanced GISTs significantly. (aacrjournals.org)
  • Interactions between the Bcr-Abl kinase inhibitor STI-571 (imatinib mesylate) and a novel microtubule-targeting agent (MTA), pyrrolo-1,5-benzoxazepine (PBOX)-6, were investigated in STI-571-sensitive and -resistant human chronic myeloid leukemia (CML) cells. (aspetjournals.org)
  • Imatinib mesylate is a potent inhibitor of c-kit receptor tyrosine kinase activity. (eur.nl)
  • Imatinib, the anti-proliferative agent that targets tyrosine kinase inhibitors (TKI), is a platelet-derived growth factor inhibitor. (acc.org)
  • Imatinib mesylate is a potent inhibitor of the Bcr-Abl tyrosine kinase, an oncoprotein that plays a key role in the development of chronic myeloid leukemia. (unina.it)
  • Background: Imatinib mesylate is a potent inhibitor of the Bcr-Abl, c-Kit, and platelet-derived growth factor receptor (PDGFR) tyrosine kinases. (elsevier.com)
  • Imatinib mesylate is an FDA-approved tyrosine kinase inhibitor that is used to treat several types of cancers. (bsu.edu)
  • Imatib contains Imatinib Mesylate.Imatib contains imatinib and belongs to a class of medications known as protein-tyrosine kinase inhibitor. (anticancerpharmaceuticals.com)
  • Imatinib mesylate is an inhibitor of receptor tyrosine kinase for PDGF. (medscape.com)
  • and helicase activity, suggesting a potential link between p68N Imatinib Mesylate enzyme inhibitor docking and ATPase activity. (angiogenesis-blog.com)
  • Although this substitution abolished ATPase and helicase activity as Imatinib Mesylate enzyme inhibitor expected, it did not reduce pol-prim docking on Tag or primosome activity on single-stranded DNA, indicating that Tag ATPase is dispensable for primosome activity DNA replication begins with RNA primer synthesis on single-stranded template DNA, followed by primer extension by a processive DNA polymerase. (angiogenesis-blog.com)
  • Tag also interacts physically with at least Imatinib Mesylate enzyme inhibitor three subunits of pol-prim (25,C31). (angiogenesis-blog.com)
  • Veenat includes imatinib and is a world class medicine known as protein-tyrosine kinase inhibitor. (widepharmacy.com)
  • Imatinib mesylate is a tyrosine kinase inhibitor IC50 value of 100 nM, 100 nM, 600 nM for v-Abl, c-kit, PDGFR, respectively. (peptidesteroids.com)
  • Imatinib Mesylate is a specific tyrosine kinase (abl, c-kit, and PDGFR) inhibitor and is reported to sensitize cells to radio- or chemo-therapy. (peptidesteroids.com)
  • Imatinib Mesylate is orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively. (peptidesteroids.com)
  • Imatib (Imatinib) is a 2-phenyl amino pyrimidine derivative that functions as a specific inhibitor of a number of tyrosine kinase enzymes. (applepharma.us)
  • We tested the efficiency of the tyrosine kinase inhibitor imatinib in selected patients with metastatic melanoma harboring c-Kit mutations or amplifications. (elsevier.com)
  • Patients receive oral imatinib mesylate once or twice daily on days 1-28. (clinicaltrials.gov)
  • Arm I: Patients receive oral imatinib mesylate twice daily in the absence of disease progression or unacceptable toxicity. (knowcancer.com)
  • Methods A total of 532 patients with late-chronic-phase CML in whom previous therapy with interferon alfa had failed were treated with 400 mg of oral imatinib daily. (kanker-actueel.nl)
  • Sixty patients with Chronic Myeloid Leukemia (CML) who were on oral imatinib were included in this study. (scirp.org)
  • Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor. (nih.gov)
  • We conducted an open-label, randomized, multicenter trial to evaluate the activity of imatinib in patients with advanced gastrointestinal stromal tumor. (nih.gov)
  • Imatinib induced a sustained objective response in more than half of patients with an advanced unresectable or metastatic gastrointestinal stromal tumor. (nih.gov)
  • Zhu, J., Wang, Y., Hou, M., Li, H.Y. and Zhang, J. (2007) Imatinib Mesylate Treatment for Advanced Gastrointestinal Stromal Tumor A Pilot Study Focusing on Patients Experiencing Sole Liver Metastasis after a Prior Radical Resection. (scirp.org)
  • Imatinib mesylate is used in the treatment of blood cancer (chronic myeloid leukaemia) , Blood cancer (Acute lymphocytic leukemia) and gastrointestinal stromal tumour . (1mg.com)
  • In DGC especially scirrhous gastric cancers it had been reported that secreted development elements released by cancers cells such as for example transforming growth aspect-β (TGF-β) platelet-derived development aspect (PDGF) and fibroblast development aspect-2 (FGF-2) play essential assignments for activation of fibroblasts which will be Imatinib Mesylate the predominant stromal cells in the cancers microenvironment12. (labourlists.org)
  • Here we describe the clinical and genetic response to imatinib mesylate treatment of an ETV6/ABL1-positive CML patient diagnosed in blast crisis (BC). (lu.se)
  • Malignancy likely related to an activated tyrosine kinase enzyme sensitive to imatinib mesylate. (clinicaltrials.gov)
  • Imatinib mesylate (IM) binds to the BCR-ABL protein, inhibiting its kinase activity and effectively controlling diseases driven by this kinase. (aacrjournals.org)
  • Imatinib Mesylate inhibits c-kit, PDGFR and c-ABL by perfectly binding to adenosine triphosphate (ATP)-binding sites of the c-kit protooncogene product, platelet-derived growth factor receptor (PDGFR), and abelson kinase (c-ABL). (creative-enzymes.com)
  • By inhibiting bcr-abl kinase activity, Imatinib Mesylate would induce cytogenetic remissions in the majority of chronic myeloid leukemia patients. (creative-enzymes.com)
  • Imatinib mesylate, one of the first tyrosine kinase inhibitors developed, was found effective and safe. (eurekaselect.com)
  • BMS-354825 (dasatinib) and AMN107 (nilotinib) are potent alternate Abl inhibitors with activity against many imatinib mesylate-resistant BCR-ABL kinase domain (KD) mutants, except T315I. (druglib.com)
  • To test the hypothesis that inhibition of Kit tyrosine kinase that promotes cardiac progenitor cell (CPC) survival and function may be one of the triggering mechanisms of imatinib mesylate (IM)-related cardiovascular effects, the anatomical, structural and ultrastructural changes in the heart of IM-treated rats were evaluated. (ovid.com)
  • In dog model with mast cell tumor, administration of imatinib mesylate at a dose of 10 mg/kg daily for 1-9 weeks reduced tumor growth via inhibiting tyrosine kinase. (peptidesteroids.com)
  • As this is now aconstitutively active tyrosine kinase, Imatib (Imatinib) is used to decrease bcr-abl activity.The active sites of tyrosine kinases each have a binding site for ATP. (applepharma.us)
  • Imatinib works by stopping the Bcr-Abl tyrosine-kinase. (wikipedia.org)
  • For treatment of progressive plexiform neurofibromas associated with neurofibromatosis type I, early research has shown potential for using the c-KIT tyrosine kinase blocking properties of imatinib. (wikipedia.org)
  • Hier eerst het abstract van het gepubliceerde onderzoek gevolgd door een kort citaat over waarom het M.D. Anderson Kannkercentrum deze aanpak met Imatinib Mesylate verkiest boven een beenmerg- of stamceltransplantatie. (kanker-actueel.nl)
  • We further show that micromolar concentrations of imatinib abrogate multiple signal transduction pathways implicated in RA pathogenesis, including mast cell c-Kit signaling and TNF-α release, macrophage c-Fms activation and cytokine production, and fibroblast PDGFR signaling and proliferation. (jci.org)
  • In our studies, imatinib attenuated PDGFR signaling in fibroblast-like synoviocytes (FLSs) and TNF-α production in synovial fluid mononuclear cells (SFMCs) derived from human RA patients. (jci.org)
  • The approaches employed included the use of gene silencing and the administration of small molecules, such as crenolanib and imatinib (PDGFR inhibitors) on MPM cell lines (IstMes2, Mero-14, Mero-25). (salford.ac.uk)
  • On the basis of variable expression of c-Kit and PDGFR in breast cancer and of in vitro data supporting synergy between imatinib and capecitabine, the Southwest Oncology Group conducted a phase II trial of the combination in metastatic breast cancer. (elsevier.com)
  • We report a case of a patient with Chronic Eosinophilic Leukemia (CEL) with mutation in alfa PDGFR gene exhibiting a satisfactory response to treatment with imatinib mesylate. (imedicalsociety.org)
  • Our work corroborates other studies on the efficacy of imatinib mesylate in the treatment of patients with CSF PDGFR alpha positive. (imedicalsociety.org)
  • Early resistance to imatinib was noted in 20 patients (13.6 percent). (nih.gov)
  • Compare the efficacy of 2 different doses of imatinib mesylate, in terms of molecular response rate at 12 months, in patients with newly diagnosed chronic myelogenous leukemia in chronic phase (CML-CP). (knowcancer.com)
  • Compare the safety profile of 2 different doses of imatinib mesylate in these patients. (knowcancer.com)
  • Compare the actual dose-intensity delivered in patients treated with 2 different doses of imatinib mesylate. (knowcancer.com)
  • Cohorts of 3-6 patients receive escalating doses of imatinib mesylate and vatalanib until the maximum tolerated dose (MTD) is determined. (clinicaltrials.gov)
  • To determine the doses of the combination regimen of cisplatin, imatinib mesylate, and pemetrexed that enables de-phosphorylation of platelet derived growth factor receptor (PDGF-R) on malignant mesothelioma tumor cells. (mesotheliomacenter.org)
  • 65 years) or those taking higher doses of imatinib mesylate. (hikma.com)
  • Severecongestive cardiac failure is an uncommon but recognized side effect of Imatib (Imatinib) and mice treated with large doses of Imatib (Imatinib) show toxic damage to their myocardium. (applepharma.us)
  • We investigated whether higher doses of imatinib may be more effective. (elsevier.com)
  • Severe congestive cardiac failure is an uncommon but recognized side effect of imatinib and mice treated with large doses of imatinib show toxic damage to their myocardium. (wikipedia.org)
  • The submission sought to extend the current listing for imatinib to include the treatment of four rare diseases: dermatofibrosarcoma protuberans (DFSP), hypereosinophilic syndrome/chronic eosinophilic leukaemia (HES/CEL), myelodysplastic/myeloproliferative diseases (MDS/MPD) and aggressive systemic mastocytosis (ASM). (pbs.gov.au)
  • Continuing PBS-subsidised treatment of an adult patient with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans who has previously been issued with an authority prescription for imatinib and who has demonstrated a response. (pbs.gov.au)
  • Although medical therapy is not a first-line treatment for localized dermatofibrosarcoma protuberans (DFSP), the approved molecular-targeted drug, imatinib mesylate, is an effective oral medication for unresectable, recurrent, and/or metastatic DFSP. (medscape.com)
  • OUTLINE: This is an open-label, dose-escalation study of imatinib mesylate and vatalanib. (clinicaltrials.gov)
  • Therefore, the authors evaluated the efficacy and safety of imatinib mesylate as treatment for patients with systemic mastocytosis. (eur.nl)
  • Imatinib Mesylate treatment (48 hours) of Leydig tumor cells cultured can reduce the growth rate of MA10 and LC540 cells by 50% to 60% with an IC50 of 5 umol/L. And in the 48 hours, the antiproliferative and apoptotic effect of imatinib Mesylate is dose-dependent. (creative-enzymes.com)
  • NESH protein expression switches to the adverse effect of imatinib mesylate. (semanticscholar.org)
  • This is the first study detailing the effects of imatinib mesylate on the spontaneous activity in the young and ageing prostate gland. (wiley.com)
  • INTRODUCTION: The aim of this study was to investigate the effects of imatinib mesylate on platelet aggregation and adenosine triphosphate (ATP) release in chronic myeloid leukemia patients. (tjh.com.tr)
  • Water retention and swelling are very common side effects of Imatinib mesylate. (1mg.com)
  • However, in the MTT proliferation assay, all eight Ewing tumour cell lines were found to be resistant to imatinib mesylate at concentrations ranging from 0.1 to 10 micro M. (unboundmedicine.com)
  • Despite the expression of imatinib mesylate-sensitive tyrosine kinases, Ewing tumour cells proved resistant to imatinib mesylate in vitro. (unboundmedicine.com)
  • However, in the MTT proliferation assay, all eight Ewing tumour cell lines were found to be resistant to imatinib mesylate at concentrations ranging from 0.1 to 10 micro M. CONCLUSIONS: Despite the expression of imatinib mesylate-sensitive tyrosine kinases, Ewing tumour cells proved resistant to imatinib mesylate in vitro. (unboundmedicine.com)
  • Journal of Biological Chemistry 280:35217, 2005), have been examined in Bcr/Abl + leukemia cells resistant to imatinib mesylate. (aacrjournals.org)
  • Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have myelofibrosis. (clinicaltrials.gov)
  • Imatinib inhibits this activity, inducing remarkable rates of hematological and cytogenetic remission in excess of those seen with alternative medical therapies. (nih.gov)
  • Compare clinical response, in terms of 1-year progression-free survival and rate of molecular complete remission, in patients with Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) in chronic phase who have achieved a complete cytogenetic remission to single-agent imatinib mesylate treated with imatinib mesylate, interferon alfa, and sargramostim (GM-CSF) vs imatinib mesylate and GM-K562 cell vaccine. (bioportfolio.com)
  • Before starting imatinib therapy, cytogenetic studies to confirm PDGFB gene rearrangement may be necessary for predicting the clinical response. (medscape.com)
  • In conclusion, high-dose imatinib induces complete cytogenetic responses, in most patients with chronic-phase CML after interferon failure. (elsevier.com)
  • As part of a recent phase II trial of neoadjuvant/adjuvant imatinib mesylate treatment for advanced primary and recurrent operable GISTs (Radiation Therapy Oncology Group S0132), gene expression profiling using oligonucleotide microarrays was done on tumor samples obtained before and after imatinib mesylate therapy. (nih.gov)
  • Imatinib mesylate has also been shown to increase the effect of chemotherapy in tumor cells. (knowcancer.com)
  • Giving imatinib mesylate and vatalanib together with hydroxyurea may kill more tumor cells. (clinicaltrials.gov)
  • Patients with systemic mastocytosis received imatinib mesylate orally at a dose of 400 mg once daily for 3 to 6 months. (eur.nl)
  • The design of a phase I, open label, dose finding study was chosen in order to establish a safe and tolerated dose of single agent ABL001 in CML and Ph+ ALL patients who are relapsed or refractory to or are intolerant of TKIs, and of ABL001+Nilotinib, ABL001+Imatinib and ABL001+Dasatinib in Ph positive CML patients who are relapsed or refractory to TKIs. (cancer.gov)
  • This phase II trial studies how well dasatinib, nilotinib, and imatinib mesylate works in treating patients with newly diagnosed, previously untreated chronic myeloid leukemia in which fewer than 10% of the cells in the blood and bone marrow are blast cells (immature blood cells) (chronic phase). (cancer.gov)
  • Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. (druglib.com)
  • We used N-ethyl-N-nitrosourea (ENU)-exposed Ba/F3-p210(BCR-ABL) cells to compare incidence and types of KD mutants emerging in the presence of imatinib mesylate, dasatinib, and nilotinib, alone and in dual combinations. (druglib.com)
  • Twenty different mutations were identified with imatinib mesylate, 10 with nilotinib (including only 1 novel mutation, E292V) and 9 with dasatinib. (druglib.com)
  • In a randomized trial in patients with newly diagnosed Ph+ CML in chronic phase comparing imatinib mesylate and nilotinib, severe (Grade 3 or 4) fluid retention occurred in 2.5% of patients receiving imatinib mesylate and in 3.9% of patients receiving nilotinib 300 mg twice daily. (hikma.com)
  • Effusions (including pleural effusion, pericardial effusion, ascites) or pulmonary edema were observed in 2.1% (none were Grade 3 or 4) of patients in the imatinib mesylate arm and 2.2% (0.7% Grade 3 or 4) of patients in the nilotinib 300 mg twice daily arm. (hikma.com)
  • Overall, treatment can be broken down into three main categories: 1) treatment with oral TKIs such as imatinib , dasatinib, or nilotinib. (oncolink.org)
  • THOC5 phospho-Y225 levels were assessed in the populations shown by flow cytometry following 24 h treatment with 5 μM imatinib, 150 nM dasatinib or 5 μM nilotinib. (selleckchem.com)
  • The clinical trials on this list are studying Imatinib Mesylate. (cancer.gov)
  • Using clinical pretreatment biopsy samples from a prospective neoadjuvant phase II trial, we have identified a gene signature that includes KRAB-ZNF 91 subfamily members that may be both predictive of and functionally associated with likely response to short-term imatinib mesylate treatment. (nih.gov)
  • Patient has previously been treated with imatinib mesylate except where treatment was more than 6 months previously and there is no suggestion of clinical resistance nor lack of response. (clinicaltrials.gov)
  • In this study, the clinical impact of HSCT and imatinib mesylate (IM) was retrospectively analyzed in 28 children with CML treated in our institutes from 1984 to 2008. (biomedsearch.com)
  • At the July 2007 meeting, the PBAC rejected a submission for imatinib for these rare diseases based on uncertain clinical benefit and uncertain cost-effectiveness. (pbs.gov.au)
  • Clinical and genetic studies of ETV6/ABL1-positive chronic myeloid leukaemia in blast crisis treated with imatinib mesylate. (lu.se)
  • In this brief review, we discuss the current tools for the effective management of chronic myeloid leukemia with Imatinib, providing the updated results of IRIS and RIGHT clinical trials and then the suggestions how Imatinib-treated patients should be monitored. (eurekaselect.com)
  • We have now updated the clinical outcomes including progression-free survival, disease-specific survival, and overall survival at a median follow-up of 5.1 years, and we correlate these end points with duration of imatinib therapy. (elsevier.com)
  • The study aimed to evaluate patients' characteristic, tolerability and efficacy and clinical outcome in Iranian patients who have been treated with generic imatinib. (scirp.org)
  • At first all clinical and laboratory data of patients were recorded and then all patients were treated with imatinib mesilate. (scirp.org)
  • Pegaspargase, methotrexate, dasatinib and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. (cancer.gov)
  • Giving combination chemotherapy with, rituximab, mercaptopurine, pegaspargase, methotrexate, dasatinib and imatinib mesylate may be an effective treatment for acute lymphoblastic leukemia or lymphoblastic lymphoma. (cancer.gov)
  • Together, these findings suggest that sorafenib effectively induces apoptosis in highly imatinib-resistant CML cells, most likely by inhibiting targets (e.g. (aacrjournals.org)
  • Imatinib mesylate (IM) induces remission in chronic myelogenous leukemia (CML) patients but does not eliminate leukemia stem cells (LSCs), which remain a potential source of relapse. (nih.gov)
  • Imatinib-mediated inhibition of a spectrum of signal transduction pathways and the downstream pathogenic cellular responses may provide a powerful approach to treat RA and other inflammatory diseases. (jci.org)
  • In vitro, imatinib Mesylate inhibition of PDGFRs and c-kit phosphorylation was concentration dependent, with an IC50 value of 0.1 to 0.5 uM. (creative-enzymes.com)
  • FDA has not approved Sun Pharma's Imatinib Mesylate Tablet products for this indication. (fiercepharma.com)
  • The offered 400 MG Imatinib Mesylate Tablet is made available by us for use in the hospitals and medical institutions. (centrodemedicamentos.com)
  • The 400 MG Imatinib Mesylate Tablet is guided to be taken according to the doctor's prescription and is very effective and safe. (centrodemedicamentos.com)
  • Each Imalek tablet contains 100 mg or 400 mg of Imatinib Mesylate. (clearskypharmacy.biz)
  • These two proteins could be used as putative biomarkers to evaluate the efficacy of imatinib treatment and to develop new combinatorial therapeutic approaches. (unina.it)
  • The efficacy of Imatinib treatment at inhibiting alphavirus replication was confirmed at different times post infection (6, 12, 18, and 24 hours post infection), different levels of infection (multiplicities of infection= 0.1, 1, and 10), and within different cell lines (BHK, Huh7 and HEK). (bsu.edu)
  • Imatinib Mesylate has been approved as an effective treatment for chronic myeloid leukemia. (creative-enzymes.com)
  • To determine the maximum tolerated dose of the combination of cisplatin, imatinib mesylate, and pemetrexed in metastatic malignantmesothelioma. (mesotheliomacenter.org)
  • Median duration of imatinib mesylate treatment was 29 months, with 81% of patients treated for ≥24 months (maximum 31.5 months). (aacrjournals.org)
  • This observation has implications for the selection of patients for experimental therapy with imatinib mesylate. (unboundmedicine.com)
  • In conclusion, these results suggest that imatinib could attenuate myocardial remodeling and improve left ventricular diastolic dysfunction in a hypertensive rat model by affecting platelet-derived growth factor and transforming growth factor-β1 pathway without the blood pressure-lowering effect. (ahajournals.org)
  • The results confirm those of the interim analysis and suggest that imatinib mesylate represents an effective therapeutic agent for the treatment of patients with CML in chronic phase after failure of IFN-α therapy, in blast crisis, and in accelerated phase. (aacrjournals.org)
  • In addition the knock-down of Shp2 expression, in combination with imatinib treatment, significantly reduced the activation of Erk 1/2 in KCL22R cells and produced a reversion of the KCL22R phenotype, suggesting that Shp2 plays a role in the Bcr-Abl activity-independent mechanisms of imatinib resistance. (unina.it)
  • The company has rolled-out Sun Pharma Imatinib Mesylate Savings Card program. (fiercepharma.com)
  • Sun Pharma has also launched an exclusive patient website www.imatinibrx.com providing detailed information about Imatinib Mesylate, its approved indications, side effects etc. (fiercepharma.com)
  • Sun Pharma will be supplying its Imatinib Mesylate Savings Cards to over 4,500 Oncologists. (fiercepharma.com)
  • Sensitivity to imatinib mesylate was analysed using a standard MTT proliferation assay. (unboundmedicine.com)
  • As clonal evolution could allow Bcr-Abl independent proliferation, we analyzed its impact on the outcome of 71 AP patients treated with 600 mg of imatinib mesylate. (bloodjournal.org)
  • Apoptosis of undivided cells for samples co-treated with LBH and 1μM imatinib are shown for CML CD34+CD38− and CD34+CD38+ cells in ( C ) and for normal cells in ( D ). Cell divisions were analyzed by flow cytometry based on reduction in CFSE intensity, and a proliferation index was determined using ModFit software. (nih.gov)
  • Taken together these results suggest that a reduced Shp1 expression in KCL22R cells could contribute to a continuous Shp2 activation, sustaining a Bcr-Abl activity-independent pathway of proliferation and survival to imatinib treatment. (unina.it)
  • The IC50 values for imatinib mesylate-inhibited T-cell proliferation stimulated by DCs and PHA were 3.9 μM and 2.9 μM, respectively. (peptidesteroids.com)
  • This randomized phase III trial studies how well imatinib mesylate and combination chemotherapy work in treating patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. (cancer.gov)
  • PURPOSE: This phase I trial is studying the side effects and best dose of imatinib mesylate and vatalanib when given together with hydroxyurea in treating patients with recurrent or relapsed malignant glioma. (clinicaltrials.gov)
  • PURPOSE: This randomized phase II trial is studying imatinib mesylate, interferon alfa, and GM-CSF to see how well they work compared to imatinib mesylate and vaccine therapy in treating patients with chronic phase chronic myelogenous leukemia. (bioportfolio.com)
  • In this regard, we aimed to investigate the effect of fludarabine-imatinib mesylate combination against CML blastic phase cell lines K562 and Meg-01. (tjh.com.tr)
  • Inclusion criteria included all patients diagnosed chronic phase CML which treated imatinib and their data were recorded. (scirp.org)
  • Imatinib at 400 mg daily is effective in chronic-phase chronic myeloid leukemia (CML) after interferon failure, although only a few patients achieve a molecular remission. (elsevier.com)
  • Thirty-six patients with chronic-phase CML after failure on interferon-α were treated with 400 mg imatinib twice daily. (elsevier.com)
  • Does the drug imatinib mesylate help treat patients with newly diagnosed leukemia patients? (rochester.edu)
  • In order to determine whether Ewing tumour patients may be potential candidates for imatinib mesylate therapy, we analysed the expression of the currently known imatinib mesylate-sensitive tyrosine kinases and tested sensitivity to imatinib mesylate in a panel of eight Ewing tumour cell lines in vitro. (unboundmedicine.com)
  • In vitro ko ullarda fludarabin i eren kombinasyonlar n l semik blastlar zerinde ve fludarabin ya da kladribinin imatinib mesilat ile kombinasyonlar n n KML CFU-GM h crelerine kar aditif etkinli e sahip olduklar g sterilmi tir. (tjh.com.tr)
  • Imatinib is being investigated for its effectiveness against other kinds of cancer, as well, including acute lymphocytic leukemia and hypereosinophilic syndrome (HES). (news-medical.net)
  • Giving imatinib mesylate and combination chemotherapy may work better in treating patients with Philadelphia chromosome positive acute lymphoblastic leukemia. (cancer.gov)
  • Imatinib was well absorbed, with pharmacokinetics similar to those reported in patients with chronic myeloid leukemia. (nih.gov)
  • Imatinib mesylate revolutionized the management of chronic myelogenous leukemia and represents the new standard of care for this disease. (haematologica.org)
  • The aim of this study was to obtain further insights into the Bcr-Abl activity-independent mechanisms underlying imatinib resistance, in chronic myeloid leukemia. (unina.it)
  • According to five-years experience with this drug, it is recommended that the golden standard for initial treatment of newly diagnosis chronic myeloid leukemia patients should be 400 mg Imatinib daily. (eurekaselect.com)
  • Angelo Michele Carella and Enrica Lerma, " Imatinib Mesylate in Chronic Myeloid Leukemia", Current Stem Cell Research & Therapy (2007) 2: 249. (eurekaselect.com)
  • Platelet Dysfunction in Patients with Chronic Myeloid Leukemia: Does Imatinib Mesylate Improve It? (tjh.com.tr)
  • METHODS: Platelet aggregation and ATP release induced by 5.0 mM adenosine diphosphate, 0.5 mM arachidonic acid, 1.0 mg/ mL ristocetin, and 2 μg/mL collagen were studied by whole blood platelet lumi-aggregometer in 20 newly diagnosed chronic myeloid leukemia patients before and after imatinib mesylate treatment. (tjh.com.tr)
  • DISCUSSION AND CONCLUSION: These findings indicate that a significant proportion of chronic myeloid leukemia patients have different patterns of platelet function abnormalities and imatinib mesylate has no effect on these abnormalities, with a significant impairment in ristocetin-induced platelet aggregation. (tjh.com.tr)
  • The drug which you are referring to as 'Imitinef Mercilet' is probably nothing but imatinib mesylate, which is a drug for chronic myeloid leukemia . (healthcaremagic.com)
  • In May of 2001, imatinib was approved by the FDA for the initial therapy for CML and later, Philadelphia chromosome (Ph)- positive acute lymphoblastic leukemia (ALL), by targeting the bcr-ablprotein, preventing further development of leukemia cells. (oncolink.org)
  • Imatib (Imatinib) is specific for the TK domain in abl(the Abelson proto-oncogene), c-kit and PDGF-R (platelet-derived growth factor receptor).In chronic myelogenous leukemia, the Philadelphia chromosome leads to a fusion protein of abl with bcr(breakpoint cluster region), termed bcr-abl. (applepharma.us)
  • Due in part to the development of imatinib and related drugs, the five year survival rate for people with chronic myeloid leukemia increased from 31% in 1993, to 59% in 2009, to 70% in 2016. (wikipedia.org)
  • Flow cytometric and RT-PCR analyses in a panel of eight Ewing tumour cell lines demonstrated expression of several imatinib mesylate-sensitive tyrosine kinases, including c-KIT, platelet-derived growth factor receptor, c-ABL and c-ARG. (unboundmedicine.com)
  • A hallmark of tumorous cells is an elevated metabolic rate and Imatinib successfully slows metabolism by inhibiting tyrosine kinases that are required to activate metabolic enzymes, such as hexokinase in the glycolytic pathway. (bsu.edu)
  • Also, imatinib significantly reduced the mRNA expression of collagen type I, III, and platelet-derived growth factor receptor-β phosphorylation in the hearts of SHR. (ahajournals.org)
  • In addition, imatinib reduced collagen production by inhibiting the phosphorylation of c-abl and platelet-derived growth factor receptor-β in rat cardiac fibroblasts. (ahajournals.org)
  • Severe superficial edema was reported in 1.5% of newly diagnosed CML patients taking imatinib mesylate, and in 2%-6% of other adult CML patients taking imatinib mesylate. (hikma.com)
  • In addition, other severe fluid retention (e.g., pleural effusion, pericardial effusion, pulmonary edema, and ascites) reactions were reported in 1.3% of newly diagnosed CML patients taking imatinib mesylate, and in 2%-6% of other adult CML patients taking imatinib mesylate. (hikma.com)